Skip to main content

Table 1 The clinical characteristics of the 4 subgroups in TCGA LUAD, TCGA SKCM and TCGA HNSC

From: Immune and stromal scoring system associated with tumor microenvironment and prognosis: a gene-based multi-cancer analysis

Variable TCGA LUAD TCGA SKCM TCGA HNSC
Subtypes HH HL LH LL P HH HL LH LL P HH HL LH LL P
Gender (%)/Chi-squared test      0.35      0.14      0.0016**
 Male 41 (43.2) 66 (42.6) 75 (48.4) 51 (53.1)   47 (58.0) 53 (55.8) 66 (69.5) 55 (67.9)   76 (75.2) 102 (65.4) 131 (84.0) 70 (69.3)  
 Female 54 (56.8) 89 (57.4) 80 (51.6) 45 (46.9)   34 (42.0) 42 (44.2) 29 (30.5) 26 (32.1)   25 (24.8) 54 (34.6) 25 (16.0) 31 (30.7)  
Median age (IQR)/ANOVA 66.5 (57.7–72.2) 69.4 (62.7–75.0) 63.3 (56.2–71.6) 65.3 (60.5–72.0)  < 0.0001**** 56.7 (46.4–64.8) 56.3 (45.0–71.6) 56.1 (49.0–68.7) 60.0 (46.4–70.9) 0.71 60.77 (53.51–68.99) 61.11 (55.03–69.86) 60.85 (53.03–67.88) 61.72 (53.04–69.02) 0.72
Pathologic T (%)/Chi-squared test      0.16      0.068      0.018*
 T0–2 86 (90.5) 139 (90.8) 129 (83.8) 81 (84.4)   38 (58.5) 39 (52.0) 35 (45.5) 24 (36.4)   37 (41.1) 64 (48.5) 41 (30.0) 40 (43.0)  
 T3–4 9 (9.5) 14 (9.2) 25 (16.2) 15 (15.6)   27 (41.5) 36 (48.0) 42 (54.5) 42 (63.6)   53 (58.9) 68 (51.5) 96 (70.0) 53 (57.0)  
Pathologic N (%)/Chi-squared test       < 0.0001****      0.3      0.42
 N0–1 81 (85.3) 139 (93.9) 115 (75.2) 83 (88.3)   50 (68.5) 66 (77.6) 59 (68.6) 55 (78.6)   40 (49.4) 71 (60.2) 77 (58.8) 51 (60.0)  
 N2–3 14 (14.7) 9 (6.1) 38 (24.8) 11 (11.7)   23 (31.5) 19 (22.4) 27 (31.4) 15 (21.4)   41 (50.6) 47 (39.8) 54 (41.2) 34 (40.0)  
Pathologic M (%)/Fisher's test      0.3      0.27      0.16
 M0 69 (94.5) 95 (96.0) 105 (92.1) 63 (88.7)   70 (93.3) 86 (96.6) 87 (94.6) 64 (88.9)   40 (100) 56 (100) 57 (100) 29 (96.7)  
 M1 4 (5.5) 4 (4.0) 9 (7.9) 8 (11.3)   5 (6.7) 3 (3.4) 5 (5.4) 8 (11.1)   0 0 0 1 (3.3)  
Pathologic stage (%)/Chi-squared test       < 0.0001****      0.38      0.16
 Stage I 47 (49.5) 106 (69.3) 64 (41.3) 54 (56.3)   19 (25.7) 24 (28.9) 18 (19.8) 14 (19.4)   2 (2.2) 11 (8.5) 5 (3.7) 9 (9.9)  
 Stage II 28 (29.5) 31 (20.3) 43 (27.7) 19 (19.8)   12 (16.2) 19 (22.9) 29 (31.9) 23 (31.9)   13 (14.6) 28 (21.7) 17 (12.6) 15 (16.5)  
 Stage III 16 (16.8) 11 (7.2) 39 (25.2) 14 (14.6)   38 (51.4) 37 (44.6) 39 (42.9) 28 (38.9)   18 (20.2) 20 (15.5) 24 (17.8) 17 (18.7)  
 Stage IV 4 (4.2) 5 (3.3) 9 (5.8) 9 (9.4)   5 (6.8) 3 (3.6) 5 (5.5) 7 (9.7)   56 (62.9) 70 (54.3) 89 (65.9) 50 (54.9)  
Survival rate (%)/log-rank       < 0.0001****       < 0.0001****      0.39
 3-year OS 60.7 78.4 45.5 69.2   75 85.1 60.8 79.4   56.2 65.6 52.7 54.4  
 5-year OS 41.2 55 30.2 40.1   65.1 78.4 43.2 63.3   46.2 50.3 47 47.4  
  1. LUAD lung adenocarcinoma, SKCM skin cutaneous melanoma, HNSC head and neck squamous cell carcinoma, NS not significant
  2. * < 0.05; ** < 0.01; *** < 0.001; **** < 0.0001